Doxycycline
- Generic Name
- Doxycycline
- Brand Names
- Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24N2O8
- CAS Number
- 564-25-0
- Unique Ingredient Identifier
- 334895S862
- Background
Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.
- Indication
Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:
It is also used to treat infections caused by the following gram-negative microorganisms:
- Associated Conditions
- Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection
A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Amina Aslam
- Target Recruit Count
- 188
- Registration Number
- NCT06915688
- Locations
- 🇵🇰
General hospital, Lahore, Pakistan
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
- Conditions
- GonorrheaChlamydiaSyphilisSexually Transmitted Infections (STIs)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Westat
- Target Recruit Count
- 760
- Registration Number
- NCT06738407
- Locations
- 🇺🇸
Penn Prevention, Philadelphia, Pennsylvania, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Daily Doxycycline for Early Syphillis
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT06683638
- Locations
- 🇺🇸
Public Health Sexual Health Clinic, Seattle, Washington, United States
Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT06582966
- Locations
- 🇰🇪
Kenya Medical Research Institute -KEMRI, Kisumu, Kenya
Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT06545656
- Locations
- 🇺🇸
Hope Clinic, Atlanta, Georgia, United States
Comparison Between Continuous and Pulsed Oral Doxycycline Treatment Protocols for Refractory Meibomian Gland Dysfunction
- Conditions
- Meibomian Gland DysfunctionBlepharitisDoxycycline Adverse Reaction
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of Milan
- Target Recruit Count
- 65
- Registration Number
- NCT06520007
- Locations
- 🇮🇹
ASST Santi Paolo e Carlo - Ospedale San Paolo, Milano, MI, Italy
Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 200
- Registration Number
- NCT06477185
- Locations
- 🇺🇬
Mulago National Referral Hospital, Kampala, Uganda
🇺🇬Makerere University Lung Institute, Kampala, Uganda
Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM
- Conditions
- Chlamydia (Male)Syphilis MaleGonorrhea Male
- Interventions
- Drug: WHO-recommended periodic presumptive treatment
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 2900
- Registration Number
- NCT06468462
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 50
- Registration Number
- NCT06452394
- Locations
- 🇨🇭
Kantonsspital St.Gallen, St. Gallen, SG, Switzerland
🇨🇭Clinique de Genolier, Genolier, VD, Switzerland
🇨🇭Kantonsspital Graubünden, Chur, GR, Switzerland
Adjunctive Doxycycline for Central Nervous System Tuberculosis
- Conditions
- Tuberculosis; Meningoencephalitis (Etiology)Tuberculosis, MeningealTuberculosis; Meningitis (Etiology)Tuberculosis, Central Nervous System
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 200
- Registration Number
- NCT06446245
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.